Zacks Research Comments on Stryker's Q2 Earnings (NYSE:SYK)

Stryker Co. (NYSE:SYK - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2025 EPS estimates for Stryker in a research report issued on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will earn $3.06 per share for the quarter, down from their prior estimate of $3.15. The consensus estimate for Stryker's current full-year earnings is $13.47 per share. Zacks Research also issued estimates for Stryker's Q3 2025 earnings at $3.13 EPS, FY2025 earnings at $13.29 EPS, Q1 2026 earnings at $3.05 EPS, Q2 2026 earnings at $3.28 EPS, Q3 2026 earnings at $3.28 EPS, Q4 2026 earnings at $4.78 EPS, Q1 2027 earnings at $3.92 EPS and FY2027 earnings at $16.55 EPS.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the firm earned $2.50 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the stock. Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Royal Bank of Canada increased their price target on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Barclays increased their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Stock Up 1.9%

Shares of SYK stock traded up $7.04 during trading hours on Monday, hitting $383.66. 1,099,109 shares of the company were exchanged, compared to its average volume of 1,347,413. The business has a 50 day moving average of $368.04 and a two-hundred day moving average of $376.15. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a market capitalization of $146.44 billion, a PE ratio of 49.44, a PEG ratio of 2.93 and a beta of 0.93.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio is 45.41%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

Several hedge funds have recently bought and sold shares of the company. J. W. Coons Advisors LLC boosted its stake in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC boosted its stake in shares of Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC boosted its stake in shares of Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after purchasing an additional 28 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after purchasing an additional 28 shares in the last quarter. Finally, JFS Wealth Advisors LLC boosted its stake in shares of Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after purchasing an additional 29 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.